Navigation Links
Advanced therapy offers cure for relapsed cancer patient

INDIANAPOLIS -- Testicular cancer patients who do not respond to traditional therapy can be cured with high-dose chemotherapy and a stem cell transplant, according to an Indiana University School of Medicine report in the July 26 issue of the New England Journal of Medicine.

About 90 percent of testicular cancer patients respond to traditional therapy, which involves multiple courses of cisplatin, first used successfully in the treatment of this disease by Lawrence Einhorn, M.D., at Indiana University Cancer Center in the early 1980s. That course of therapy turned a disease from a mostly fatal cancer into one of the more curable forms of cancer for men, who typically are in their 20s when diagnosed with testicular cancer.

It is rare for the NEJM to carry a retrospective study from a single institution that is not a randomized study. This review looks at the outcome of 184 patients with metastatic testicular cancer. Dr. Einhorn and colleagues demonstrated that the disease is potentially curable with a high dose chemotherapy and stem cell transplant using cells harvested from the patient before the initial chemotherapy infusion.

The patients received carboplatin chemotherapy at five times the dosage administered to men receiving initial therapy. A side effect of the high dosage is a reduction of blood cells so a stem cell transplant is given to replenish the body’s immune system through a process similar to a blood transfusion. Three to four weeks later the entire process is repeated.

“The message for patients is that through research, diligence and new technologies there is hope,” said Dr. Einhorn, professor of medicine at the Indiana University Melvin and Bren Simon Cancer Center and the lead author of the study. “The bar is steadily being raised and more patients are being saved.”

“This review confirms that high-dose chemotherapy combined with a stem cell transplant can provide a cure for a group of patients with relaps ed testicular cancer,” said Rafat Abonour, M.D., associate professor of medicine in the division of hematology/oncology and associate dean for clinical research at the IU School of Medicine.

Although the number of relapsed testicular cancer patients is small, the IU Simon Cancer Center treats a majority of them. As a leader in this treatment, the researchers were able to collect the necessary data for the NEJM retrospective.

For the patients each year who are treated with this therapy, there is renewed hope. “This is new medicine and it tells patients that cures are on the horizon,” said Stephen D. Williams, M.D., director of the IU Simon Cancer Center and a co-author of the paper.   (Indiana University)


'"/>




Related medicine news :

1. Innovative device aids in advanced heart failure
2. Advanced STD programs required
3. Light therapy devotes new hope in advanced lung cancer
4. Hope For Patients With Advanced Breast Cancer
5. Race an important links to the risk of advanced colorectal cancer
6. HIV Vaccine Field Trials In Advanced Stage
7. Twin Treatment Could Be Used Increase Survival Rates In Advanced Melanoma
8. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
9. Eddie Thompson Receives Advanced Cancer Treatment
10. PSA Can Predicts The Treatment Response In Advanced Prostate Cancer
11. Rapid Aging of Arteries In People With Advanced Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
(Date:10/12/2017)... ... 12, 2017 , ... Farm Forward joins Bon ... leading institutions in announcing the launch of the Leadership Circle , a ... are raised for food. , Founding members of the Leadership Circle also include ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
Breaking Medicine Technology: